CII
ONCT

CR Intrinsic Investors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

CR Intrinsic Investors’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-344
Closed -$3.18M – 414
2013
Q2 		$3.18M Buy
+344
New +$2.65M 0.11% 227

Other funds holding ONCT

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CR Intrinsic Investors's ONCT Position: Q3 2013 in Review

CR Intrinsic Investors sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2013, closing a stake of 344 shares — an estimated $3.18M sold.

CR Intrinsic Investors first reported a position in ONCT in Q2 2013 and held it in 1 quarter. The position peaked at $3.18M in Q2 2013. 58 funds tracked by Wall St. Rank hold ONCT as of Q3 2013.

  • CR Intrinsic Investors reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2013 after selling out during the quarter.
  • CR Intrinsic Investors sold 344 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2013, an estimated $3.18M.
  • CR Intrinsic Investors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 1 quarter.
  • CR Intrinsic Investors's Oncternal Therapeutics, Inc. Common Stock position peaked at $3.18M in Q2 2013.
  • 58 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2013.

Based on CR Intrinsic Investors's 13F filing for Q3 2013, filed 14 Nov 2013.